Skip to content


Jyseleca (filgotinib) is a small molecule pharmaceutical. Filgotinib was first approved as Jyseleca on 2020-09-24. It has been approved in Europe to treat rheumatoid arthritis. The pharmaceutical is active against tyrosine-protein kinase JAK1. In addition, it is known to target tyrosine-protein kinase JAK3, non-receptor tyrosine-protein kinase TYK2, and tyrosine-protein kinase JAK2.
Trade Name Jyseleca
Common Name Filgotinib
Indication rheumatoid arthritis
Drug Class Tyrosine kinase inhibitors
Get full access now